Compare GSK plc (GSK) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs HubSpot Inc — how do they compare? GSK plc trades at $52.69 (market cap $101.34B), while HubSpot Inc trades at $218.73 (market cap $11.02B). The key difference: GSK plc is far larger — about 9.2× HubSpot Inc's market cap, and GSK plc pays a 3.49% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals.
| GSK | HUBS | |
|---|---|---|
Market Cap | $101.34B | $11.02B |
Sector | Health | Technology |
52-Week High | $61.18 | $560.90 |
52-Week Low | $36.20 | $170.39 |
Enterprise Value | $121.95B | $9.58B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
HubSpot (HUBS) trades at $209.68, down 3.64% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $268.75. The company reported Q1 2026 EPS of $2.72, beating estimates, and shows strong revenue growth, reaching $3.13B in 2025. Positive sentiment is driven by AI integration and customer expansion, with 80.85% of analysts rating it a Buy.
The outlook for HUBS is positive, supported by robust revenue growth, expanding AI capabilities, and consistent earnings beats. Key risks include high valuation multiples and competitive pressures in the CRM space. Investors should monitor execution on AI monetization and margin improvement for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
